Skip to main page content
U.S. flag

An official website of the United States government

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Search Results

730 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Single cell profiling of hematopoietic stem cell transplant recipients reveals TGF-β1 and IL-2 confer immunoregulatory functions to NK cells.
Mathews JA, Borovsky DT, Reid KT, Murphy JM, Colpitts SJ, Carreira AS, Moya TA, Chung DC, Novitzky-Basso I, Mattsson J, Ohashi PS, Crome SQ. Mathews JA, et al. Among authors: mattsson j. iScience. 2024 Nov 18;27(12):111416. doi: 10.1016/j.isci.2024.111416. eCollection 2024 Dec 20. iScience. 2024. PMID: 39720529 Free PMC article.
Propensity score matching analysis comparing the efficacy of Ruxolitinib to historical controls in second-line or beyond treatment for chronic GvHD after steroid failure.
Novitzky-Basso I, Linn SM, White J, Elemary M, Xenocostas A, Deotare U, Kelly K, Hamad N, Tan S, Culos S, Law A, Kumar R, Mattsson J, Kim DDH. Novitzky-Basso I, et al. Among authors: mattsson j. Bone Marrow Transplant. 2023 Sep;58(9):1024-1032. doi: 10.1038/s41409-023-02020-5. Epub 2023 Jun 26. Bone Marrow Transplant. 2023. PMID: 37365296
Prognostic implication of pre-transplant FEV1 on long-term outcomes following allogeneic hematopoietic stem cell transplantation.
Novitzky-Basso I, Lam W, Chiarello C, Pasic I, Law AD, Michelis FV, Gerbitz A, Viswabandya A, Lipton JH, Kumar R, Mattsson J, Messner HA, Marras TK, Mittoo S, Kim DDH. Novitzky-Basso I, et al. Among authors: mattsson j. Eur J Haematol. 2023 Nov;111(5):687-696. doi: 10.1111/ejh.14062. Epub 2023 Jul 25. Eur J Haematol. 2023. PMID: 37491877
A Single-center, Real-world Experience of Chronic GVHD Treatment Using Ibrutinib, Imatinib, and Ruxolitinib and its Treatment Outcomes.
Linn SM, Novitzky-Basso I, Abduljalil O, Pasic I, Lam W, Law A, Michelis FV, Gerbitz A, Viswabandya A, Lipton J, Kumar R, Mattsson J, Kim DDH. Linn SM, et al. Among authors: mattsson j. Hematol Oncol Stem Cell Ther. 2023 Jul 20;17(1):60-71. doi: 10.56875/2589-0646.1111. Hematol Oncol Stem Cell Ther. 2023. PMID: 37581458 Free article.
Single centre retrospective analysis of extracorporeal photopheresis (ECP) therapy in patients heavily pre-treated for chronic graft-versus-host disease (cGvHD) with steroid failure.
Linn SM, Novitzky-Basso I, Patriquin C, Pasic I, Lam W, Law A, Michelis FV, Gerbitz A, Viswabandya A, Lipton J, Kumar R, Mattsson J, Barth D, Kim DDH. Linn SM, et al. Among authors: mattsson j. Leuk Res. 2023 Nov;134:107387. doi: 10.1016/j.leukres.2023.107387. Epub 2023 Sep 9. Leuk Res. 2023. PMID: 37734221
Propensity Score Matching Analysis Comparing the Efficacy and Steroid Tapering Benefit of Extracorporeal Photopheresis to Best Available Therapy in Third-Line or Beyond Treatment for Chronic GvHD.
Novitzky-Basso I, Patriquin C, Linn SM, Chiarello C, Pasic I, Lam W, Law A, Michelis FV, Gerbitz A, Viswabandya A, Lipton J, Kumar R, Mattsson J, Barth D, Kim DDH. Novitzky-Basso I, et al. Among authors: mattsson j. Transplant Cell Ther. 2023 Dec;29(12):773.e1-773.e10. doi: 10.1016/j.jtct.2023.09.021. Epub 2023 Oct 4. Transplant Cell Ther. 2023. PMID: 37797719 Free article.
Outcomes of Antithymocyte Globulin-Post-Transplantation Cyclophosphamide-Cyclosporine-Based versus Antithymocyte Globulin-Based Prophylaxis for 10/10 HLA-Matched Unrelated Donor Allogeneic Hematopoietic Cell Transplantation.
Salas MQ, Alfaro-Moya T, Atenafu EG, Datt Law A, Lam W, Pasic I, Novitzky-Basso I, Santos Carreira A, Chen C, Michelis FV, Gerbitz A, Howard Lipton J, Kim DDH, Kumar R, Mattsson J, Viswabandya A. Salas MQ, et al. Among authors: mattsson j. Transplant Cell Ther. 2024 May;30(5):536.e1-536.e13. doi: 10.1016/j.jtct.2024.01.075. Epub 2024 Jan 27. Transplant Cell Ther. 2024. PMID: 38281592
Flow cytometry-based measurable residual disease (MRD) analysis identifies AML patients who may benefit from allogeneic hematopoietic stem cell transplantation.
Lucero J, Alhumaid M, Novitzky-Basso I, Capo-Chichi JM, Stockley T, Gupta V, Bankar A, Chan S, Schuh AC, Minden M, Mattsson J, Kumar R, Sibai H, Tierens A, Kim DDH. Lucero J, et al. Among authors: mattsson j. Ann Hematol. 2024 Apr;103(4):1187-1196. doi: 10.1007/s00277-024-05639-6. Epub 2024 Jan 30. Ann Hematol. 2024. PMID: 38291275
730 results